UBS AM’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.66M | Buy |
190,104
+59,534
| +46% | +$832K | ﹤0.01% | 2020 |
|
|
2025
Q1 | $1.76M | Buy |
130,570
+14,788
| +13% | +$199K | ﹤0.01% | 2050 |
|
|
2024
Q4 | $2.22M | Buy |
115,782
+26,286
| +29% | +$504K | ﹤0.01% | 1984 |
|
|
2024
Q3 | $2.04M | Buy |
89,496
+20,166
| +29% | +$459K | ﹤0.01% | 2024 |
|
|
2024
Q2 | $902K | Buy |
69,330
+41,021
| +145% | +$534K | ﹤0.01% | 2430 |
|
|
2024
Q1 | $496K | Buy |
28,309
+13,148
| +87% | +$230K | ﹤0.01% | 2286 |
|
|
2023
Q4 | $330K | Hold |
15,161
| – | – | ﹤0.01% | 2407 |
|
|
2023
Q3 | $233K | Sell |
15,161
-8,460
| -36% | -$130K | ﹤0.01% | 2485 |
|
|
2023
Q2 | $601K | Hold |
23,621
| – | – | ﹤0.01% | 2246 |
|
|
2023
Q1 | $601K | Buy |
23,621
+4,151
| +21% | +$106K | ﹤0.01% | 2246 |
|
|
2022
Q4 | $569K | Buy |
+19,470
| New | +$569K | ﹤0.01% | 2130 |
|